Select a company

Go

Company Stage

  • Private (seed)
  • Private (post-seed)
  • Quoted

Sector

  • Biotech
  • Healthcare
  • Cleantech
  • Technology
  • Other

University

  • University of Bath
  • University of Bristol
  • University of Cardiff
  • University of Glasgow
  • University of Leeds
  • King's College London
  • Queen Mary, University of London
  • University of Manchester
  • University of Nottingham
  • University of Oxford
  • University of Sheffield
  • University of Southampton
  • University of Surrey
  • Swansea University
  • University of York
  • Other

Stakeholder

  • IP Group
  • IP Venture Fund
  • IP Venture Fund II
  • Top 10 Holdings
    by value
Medical Equipment & Supplies

University: Oxford

Company Stage: Private (post-seed)

Website: http://www.inhibox.com

Inhibox

Traditional approaches to drug discovery have focussed on making and testing large number of compounds in the laboratory. Inhibox, however, is based on using novel software to screen large libraries of molecules against therapeutic targets in order to predict which molecules are likely to be appropriate candidates for new drugs. This combination of screening software, very large compound libraries and computing power enables Inhibox to undertake a range of drug discovery services and collaborations. Inhibox is also undertaking a number of proprietary programmes.

As at 30 June 2014

IP Group holding

IP Venture Fund* holding

21.8%

21.8%
 

*IP Group has a 10%
economic interest in IP
Venture Fund

Holdings represent undiluted beneficial equity interest excluding debt